ABSTRACT
/PTEN Null melanoma proliferation required combined blockade of PI3KD, G and J, and was insensitive to PI3KE blockade. In GEM models, isoform-selective PI3K inhibition elicited cytostatic effects, but significantly potentiated melanoma regression in response to BRAF V600E pathway-targeted inhibition. Interestingly, PI3K inhibition forestalled the onset of MEK inhibitor resistance in two independent GEM models of BRAF V600E -driven melanoma. These results suggest that combination therapy with PI3K inhibitors may be a useful strategy to extend the duration of clinical response of BRAF-mutated melanoma patients to BRAF V600E pathway-targeted therapies.
(Words: 165)
STATEMENT OF SIGNIFICANCE
Although BRAF V600E pathway-targeted therapies elicit melanoma regression, the onset of drug resistance limits the durability of response. Here we show that combined treatment with PI3K inhibitors significantly forestalled the onset of MEK1/2 inhibitor resistant disease in BRAF-mutated GEM melanoma models. These results provide a conceptual framework for the combined deployment of BRAF V600E plus
INTRODUCTION
Over the past fifteen years, key genetic lesions that initiate melanomagenesis, promote disease progression and remain necessary for melanoma maintenance have been identified (1, 2) .
Approximately 50% of melanomas express mutationally activated BRAF V600E , leading to constitutive activation of the BRAF V600E oMEK1/2oERK1/2 mitogen-activated protein (MAP) kinase pathway (3) .
The importance of this pathway in melanoma maintenance is highlighted by the ability of BRAF V600E pathway-targeted inhibitors to elicit dramatic tumor regression in BRAF-mutated, advanced melanoma patients (4) (5) (6) . Although the response rate of such patients is high, the depth and durability of response is limited by the onset of drug resistant disease that is largely refractory to additional BRAF V600E pathwaytargeted therapy (7, 8) . Therefore, it is critical to identify signaling pathways that contribute to de novo or acquired drug resistance, and to determine if pharmacological blockade of these pathways can increase the response rate or the durability of response to BRAF V600E pathway-targeted therapies. Although multiple mechanisms of acquired drug resistance have been documented, it remains unclear the extent to which parallel inhibition of signaling pathways will enhance melanoma patient responses (9, 10 /PTEN Null melanomas (11) . In addition, although a pan-class I PI3K inhibitor (BKM120)
significantly potentiated the ability of a BRAF V600E inhibitor (LGX818) to induce regression of autochthonous BRAF V600E /PTEN Null melanomas, BKM120 was largely ineffective as a single agent (11) .
Given the frequency of alterations in PI3'-lipid signaling in BRAF-mutated melanoma (12) (13) (14) (15) , we wished to explore the role of PI3K signaling in melanoma progression and maintenance, as well as the therapeutic implications of targeting this pathway using isoform-selective inhibitors. term cell proliferation and had no effect on long-term colony formation (Figs. 1B & 1C) . Indeed, there was a greater than 10-fold difference between the concentration of BYL719 required for 50% inhibition of proliferation (GI 50 ) of BPC versus B10C cells (Fig. 1D) To examine the effects of PI3KD blockade on signal pathway activity, extracts of BPC or B10C melanoma cells treated with BYL719 (5PM) were subjected to immunoblot analysis (Fig. 1E) . In BPC cells, BYL719 elicited a complete and sustained inhibition of pAKT (pS473) over 72 hours. We also noted diminished phosphorylation of downstream pathway components of PI3KoAKT signaling including PRAS40 and 4E-BP1 (Fig. 1E) . By contrast, BYL719-treated B10C cells displayed only a partial and transient inhibition of pAKT with almost no effect on pPRAS40 or p4E-BP1.
Since BRAF V600E and PI3K signal cooperatively through mTORC to regulate melanoma cell proliferation (20) , we investigated whether PI3KD inhibition would enhance the effects of BRAF V600E inhibition in BPC or B10C melanoma cells. While single agent BRAF V600E (LGX818) (21) or PI3KD (BYL719) inhibition potently suppressed BPC melanoma cell proliferation, combined treatment elicited a significantly greater inhibition of cell proliferation at 24, 48, and 72 hours (Fig. 1F) . Further, while inhibition of PI3KD suppressed pPRAS40, pRPS6 and p4EB-P1 in BPC melanoma cells, combined inhibition of both BRAF V600E and PIK3CA H1047R signaling elicited a more robust inhibition of these phosphorylation events (Fig. 1G ). Similar observations were made in the independently derived BP 2 C melanoma cell line (Fig. S1C) . By contrast, while BRAF V600E inhibition (LGX818) potently suppressed B10C cell proliferation, addition of BYL719 did not significantly enhance the anti-proliferative effects of BRAF V600E inhibition at any time point (Fig. 1F) . In B10C cells, LGX818 inhibited pERK but had little effect on pRPS6 or p4E-BP1 (Fig. 1G ). /PIK3CA H1047R melanomas indicated the need to dose BYL719 twice daily to achieve maximal target inhibition (Fig. S1D ).
Single agent BYL719 initially elicited modest melanoma regression (<30%), followed by a prolonged cytostatic effect (Fig. 1H ). By contrast, single agent LGX818 elicited profound melanoma regression.
Importantly, the combination of BYL719 plus LGX818 promoted significantly more potent melanoma regression than that observed with LGX818 monotherapy (Fig. 1H) . Analysis of the best overall response by waterfall plot indicated that only 2/8 mice treated with BYL719 displayed >30% melanoma regression, which qualifies as a partial response (PR) by modified RECIST 1.1 guidelines (Fig. 1I ) (23) .
By contrast, 7/7 mice treated with LGX818 exceeded the 30% regression threshold, as did 8/8 mice receiving BYL719+LGX818. Finally, combined treatment with LGX818 plus BYL719 provided significantly superior melanoma regression compared to single agent LGX818 therapy (Fig. 1I ).
Research. Analysis of glioblastoma, breast or prostate cancer models suggests that PI3'-kinase-E (PI3KE/PIK3CB) is the predominant driver of PI3'-lipid production in PTEN Null tumors (24, 25 ).
Consequently, we tested the effects of PI3KE selective inhibition on the proliferation of human (Fig. 2F) . However, when the cells were treated with a fixed concentration of IPI145 (2.5PM) in the presence of BYL719, the combination elicited a more robust anti-proliferative response similar to the effects of GDC-0032 (Fig. 2F) . Furthermore, while single agent treatment of WM9 cells with either BYL719 or IPI145 elicited only a modest reduction in pAKT with little or no effect on downstream pathway components, the combination of BYL719 plus IPI145 elicited a complete and sustained inhibition of pAKT that mirrored the effects of GDC-0032 (Fig. 2G) (Fig. S4B) . Moreover, both GDC-0032 and GDC-0941 displayed equivalent GI 50 values in SK-MEL-239 cells (Fig. S4C) . The combined use of GDC-0032 plus GDC-0973 elicited robust suppression of pAKT and pERK, as well as an even more robust suppression of pRPS6 and p4E-BP1 than that achieved with either single agent (Fig. S4D) . Finally, whereas single agent GDC-0973 or GDC-0032 suppressed SK-MEL-239 cell proliferation, combined treatment elicited a significant reduction in proliferation compared to either single agent alone (Figs. S4E) .
Collectively these results indicate that, in at least one BRAF V600E /PTEN WT human melanoma cell line, PI3KE activity is dispensable for proliferation and that these cells rely upon the combined activities of PI3KD G and/or J.
Although the majority of BRAF-mutated melanoma patients experience initial tumor regression in response to BRAF V600E pathway-targeted therapies, the durability of response is limited by the onset of drug resistant disease (6) . Therefore, we wished to test if inhibition of class I PI3K isoform(s) would influence the development of resistance to inhibitors that target BRAF V600E signaling. We initially tested this question using vehicle-treated BRAF V600E/ PTEN Null melanoma-bearing mice enrolled in the study described in Fig. 3C . When these mice (n=8) were near to end-stage, they were randomly re-assigned to receive extended treatment with either GDC-0973 monotherapy or combined GDC-0973 plus GDC-0032. These mice received a reduced dose of GDC-0973 (2mg/kg) and a full dose GDC-0032 
monotherapy treatment. As expected, the transplanted tumor displayed resistance to GDC-0973 and grew progressively over 50 days. At this time, half of the mice were randomly re-assigned to receive GDC-0973 plus GDC-0032 combination therapy, while the rest continued to receive GDC-0973 monotherapy (Fig. 4C) . The mice receiving GDC-0973 plus GDC-0032 combination therapy experienced potent tumor cytostasis, suggesting that PI3K pathway activity is necessary for the sustained growth of a melanoma that has developed resistance to a MEK1/2 inhibitor. BRAF-mutated melanoma, there is no compelling rationale to invoke such mechanisms. Importantly, the correlation between PI3K pathway activation and melanoma growth rate indicates that PI3K catalytic isoforms are relevant drug targets in the treatment of BRAF V600E /PTEN Null melanoma.
The "oncogene addiction" hypothesis posits that, despite a high burden of genetic damage, tumors remain dependent on the sustained activity of one or a small number of oncogenes for maintenance of the malignant phenotype (33) . As a corollary, inhibition of the oncogene(s) to which a tumor is addicted can elicit profound tumor regression (34 (GDC-0032), demonstrating no role for PI3KE in these cells. It is tempting to speculate that PI3KE may play a role in the proliferation of melanomas in which RAC1 is mutated or amplified, as PI3KE is a direct target of activated RAC1-GTP (1, 35) . authenticated by genomic sequencing as previously described (38) . Mouse melanoma cell lines B10C, BPC, and BP 2 C were established as described previously and authenticated by PCR and immunoblot analyses (11) . Efficient generation of melanoma cell lines from our various GEM models requires the silencing of the Cdkn2a locus encoding INK4A and ARF. Mouse or human melanoma cell lines were cultured as described previously (11) . Pathway-targeted pharmacological agents were obtained from various colleagues in the public or private sector or from commercial sources (see Supplementary Table   1 for provenance).
Proliferation and Growth Assays
Melanoma cell proliferation was assessed over 72-hours by seeding 5 x 10 4 cells in 12-well dishes.
Cells were treated with the various pharmacological agents as described with viable cells enumerated using a Countess ® cell counter (Invitrogen). In addition, melanoma cells were seeded and treated with pharmacological agents as described for 72 hours at which time viable cells were stained with crystal violet and quantified by solubilization in 33% acetic acid with A562 absorbance assessed. GI 50 assays were performed by seeding 8.0 x 10 3 cells in a 96-well plate and treating cells with pharmacological agents as described for 72 hours at which time viable cells were stained with Crystal Violet and quantified by solubilization in 33%(v/v) acetic acid with A562 absorbance assessed. At least three independent experiments, performed in biological triplicate, were completed for all 72-hour assays.
Research. 
days in the absence or presence of various agents with cell colonies fixed and stained with Crystal Violet.
Immunoblot Analysis
Cell lysates were generated for analysis of 50Pg aliquots by immunoblotting as described previously (20) . Membranes were stained with primary antibodies with antigen-antibody complexes detected using fluorescent goat anti-Rabbit IRDye 800 or goat anti-Mouse IRDye 680 secondary antibodies (LI-COR Biosciences) and visualized with a LI-COR infrared imaging system (Odyssey Fc). Immunoblot data were analyzed using Image Studio v2.0 software (LI-COR Biosciences).
Experimental Animals
The UCSF Institutional Animal Care and Use Committee (IACUC) reviewed and approved all animal procedures. Tyr::CreER, BRaf
Lat-1047R mice, maintained on an outbred background, were intercrossed to generate experimental mice which were genotyped as previously described (11, 12) .
Melanocyte-specific Cre activity was induced in adult mice by topical application of 1.5Pl of 5mM 4-hydroxytamoxifen (4-HT, 70% Z-isomer, in 100% Ethanol, Sigma Aldrich) to shaved back skin. Animals were euthanized based on a body conditioning score (39) or when tumor volume >2cm 3 , whichever occurred first. At necropsy, tissue was snap frozen in liquid nitrogen. Tissue was homogenized in RIPA buffer using the Tissue Lyser II (Qiagen ® ) for immunoblotting as described previously (11) .
Treatment of Mice with Pathway-Targeted Inhibitors
Melanoma-bearing mice were divided among treatment arms to give equal distribution of tumor volume and gender when the mean tumor volume of the cohort exceeded 500mm 
Statistical Analysis
All quantitative data is represented as means ± SEM. GraphPad Prism 6 statistical software was 
39.
Ullman-Cullere MH, Foltz CJ. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci. 1999;49:319-23. (C) Fragments of a single GDC-0973 resistant tumor from (A) were implanted into eight immunocompromised mice and allowed to grow into measurable tumors over 50 days with daily administration of GDC-0973 (2mg/kg). At that time, mice were randomized to receive either combination GDC-0973 (2mg/kg) plus GDC-0032 (22.5mg/kg) (green) or continuation of single agent GDC-0973 (2mg/kg) (pink). Tumor sizes were measured weekly and plotted as described previously. Tumor sizes are displayed as the average percent change in tumor size from the crossover point, with error bars indicating SEM.
FIGURE LEGENDS
(D) BRAF V600E /PIK3CA H1047R melanomas were initiated in 13 adult Tyr::CreER; BRaf CA ; Pik3ca lat/lat mice and 8 weeks later they were randomized by tumor size and sex for treatment with GDC-0973 (2mg/kg, q.d., n=7) or GDC-0973 plus BYL719 (50mg/kg, b.i.d., n=6). Melanoma growth or regression was measured weekly over the course of 106 days of drug treatment. Tumor sizes were measured weekly and plotted as described previously, with error bars indicating SEM. 
